HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Results for CTL/CD8+ T-Cell Epitope Variants

Filter results by Mutation Type:

MICSAAEKLWVTVYYGVP gp160(26-43) human epitope
   NTAENLWVTVYYGVP gp160(29-43) B*44:02 human epitope
   SATEKLWVTVYYGVP gp160(29-43) human epitope
    AVEKLWVTVYY gp160(30-40) B*18:01 humanized mouse epitope
    AiEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AaEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AeEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AVkKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AVgKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AVEKsWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AVEKLWVTiYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
    AAENLWVTVYY gp160(30-40) B*44 human epitope
    AENLVWTVYY gp160(30-40) B44 human epitope
    AVEKLWVTVYYGVPA gp160(30-44) mouse epitope
    VMGNLWVTVYYGVPVWK gp160(30-46) C*07 human epitope
    AAENLWVTVYYGVPVWK gp160(30-46) human epitope
    vggNLWVTVYYGVPVWK gp160(30-46) subtype-specific susceptible form
    AAEQLWVTVYYGVPVWKEAT gp160(30-49) A11 human epitope
    AAEQLWVTVYYGVPVWKEAT gp160(30-49) A11 human epitope
    ATEKLWVTVYYGVPVWKEAT gp160(30-49) human epitope
    ATEKmWVTVYYGVPVWKEAT gp160(30-49) observed variant
    ATEKLWVTVYYGaPVWKEAT gp160(30-49) observed variant
    ATEKLcVTVYYGVPVWKEAT gp160(30-49) observed variant
    ATEKLWVTVhYGVPVWKEAT gp160(30-49) observed variant
    ATEKLWVTVYYGVPaWKEAT gp160(30-49) observed variant
    ATEKLWVTVYhGVPVWKEAT gp160(30-49) observed variant
     AENLWVTVY gp160(31-39) B*15:17 human epitope
     AENLWVTVY gp160(31-39) B*15:40 human epitope
     AENLWVTVY gp160(31-39) B*18 human epitope
     AENLWVTVY gp160(31-39) B*18:01 human epitope
     AENLWVTVY gp160(31-39) B*18:01 human epitope
     AdNLWVTVY gp160(31-39) susceptible form
     tdNLWVTVY gp160(31-39) susceptible form
     tEdLWVTVY gp160(31-39) escape documented in this paper
     eEdLWVTVY gp160(31-39) escape documented in this paper
     AEdsWVTVY gp160(31-39) escape documented in this paper
     AENLWVTVY gp160(31-39) B*18:01 human epitope
     TEdLWVTVY gp160(31-39) escape documented in this paper
     eEDLWVTVY gp160(31-39) escape documented in this paper
     AEdsWVTVY gp160(31-39) escape documented in this paper
     AENLWVTVY gp160(31-39) B*18:01 human epitope
     AdNLWVTVY gp160(31-39) susceptible form
     AEdsWVTVY gp160(31-39) escape documented in this paper
     AENLWVTVY gp160(31-39) B*44 human epitope
     AENLWVTVY gp160(31-39) B*44 human epitope
     AENLWVTVY gp160(31-39) B44 human epitope
     tENLWVTVY gp160(31-39) susceptible form
     AkNLWVTVY gp160(31-39) non-susceptible form
     AgNLWVTVY gp160(31-39) non-susceptible form
     AaNLWVTVY gp160(31-39) non-susceptible form
     AENLWVTVY gp160(31-39) B44 human epitope
     AENLWVTVY gp160(31-39) B44 human epitope
     AENLWVTVY gp160(31-39) B44 human epitope
     AENLWVTVY gp160(31-39) B44 human epitope
     AENLWVTVY gp160(31-39) B44 human epitope
     AENLWVTVY gp160(31-39) B*44:03 human epitope
     AaNLWVTaY gp160(31-39) diminished response
     AEkLWVTVY gp160(31-39) diminished response
     AENLgVTVY gp160(31-39) diminished response
     tENLWVTVY gp160(31-39) susceptible form
     vENsWVTVY gp160(31-39) diminished response
     tEkLWVTVY gp160(31-39) diminished response
     AgNLWVTVY gp160(31-39) diminished response
     AaNLWVTVY gp160(31-39) escape documented in this paper
     AkNLWVTVY gp160(31-39) escape documented in this paper
     tENLWVTiY gp160(31-39) susceptible form
     AENLWVTVY gp160(31-39) B*44:03 human epitope
     AEkLWVTVY gp160(31-39) escape documented in this paper
     tENLWVTVY gp160(31-39) susceptible form
     vENLWVTVY gp160(31-39) inferred escape
     AkNLWVTVY gp160(31-39) escape documented in this paper
     AgNLWVTVY gp160(31-39) escape documented in this paper
     AENLWVTiY gp160(31-39) observed variant
     AEdLWVTVY gp160(31-39) observed variant
     AaNLWVTVY gp160(31-39) escape documented in this paper
     AEsLWVTVY gp160(31-39) observed variant
     AdNLWVTVY gp160(31-39) observed variant
     AaNLWVTaY gp160(31-39) escape documented in this paper
     AENsWVTVY gp160(31-39) observed variant
     vENsWVTVY gp160(31-39) escape documented in this paper
     AEtLWVTVY gp160(31-39) observed variant
     tENLWVTiY gp160(31-39) susceptible form
     tEkLWVTVY gp160(31-39) escape documented in this paper
     AENLWVTVY gp160(31-39) C*02 human epitope
     AENLWVTVY gp160(31-39) human epitope
     AENLWVTVYY gp160(31-40) A*29 human epitope
     AENLWVTVYY gp160(31-40) A*68:02 human epitope
     AENLWVTVYY gp160(31-40) B*18 human epitope
     AENLWVTVYY gp160(31-40) B*44:02 human epitope
     AENLWVTVYY gp160(31-40) C*04 human epitope
     TEKLWVTVYYGVPVWKEATTTLFCA gp160(31-55) B18 human epitope
     TEKLWVTVYYGVPVWKEATTTLFCA gp160(31-55) B18 human epitope
      DNLWVTVYY gp160(32-40) B44 human epitope
      EKLWVTVYY gp160(32-40) C*06:02, C*07:02 human epitope
      ENLWVTVYY gp160(32-40) human epitope
      EQLWVTVYYGVPVWKEATTT gp160(32-51) human epitope
       KLWVTVYYGV gp160(33-42) A*02:01 human epitope
       KLWVTVYYGV gp160(33-42) A*02:01 human epitope
       KLWVTVYYGV gp160(33-42) A*02:01 human epitope
       KLWVTVYYGV gp160(33-42) A2 human epitope
       nwWVTVYYGV gp160(33-42) observed variant
       NLWVTVYYGV gp160(33-42) A2 human epitope
       NLWVTVYYGV gp160(33-42) A2 human epitope
       kLWVTVYYGV gp160(33-42) observed variant
       qLWVTVYYGV gp160(33-42) observed variant
       dLWVTVYYGV gp160(33-42) observed variant
        LWVTVYYGV gp160(34-42) A*02:01 human epitope
        LWVTVYYGV gp160(34-42) A*02:01 human epitope
        LWVTVYYGV gp160(34-42) A*02:01 human epitope
        LWVTVYYGVPVWKDA gp160(34-48) A*03:01 human epitope
        LWVTVYYGVPVWKEAKTT gp160(34-51) human epitope
        LWVTVYYGVPVWKEATTTLFCA gp160(34-55) A2 human epitope
        LWVTVYYGVPVWKEATTTLFCA gp160(34-55) A2 human epitope
        wWVTVYYGVPVWKEATnTLFCA gp160(34-55) observed variant
          VTVYYGVPV gp160(36-44) A2 human epitope
          VTVYYGVPV gp160(36-44) A2 human epitope
          VTVYYGVPV gp160(36-44) A2 human epitope
          VTVYYGVPVWK gp160(36-46) A*03:01 human epitope
          VTVYYGVPVWR gp160(36-46) A*11 human epitope
          VTVYYGVPVWR gp160(36-46) A11 human epitope
          VTVYYGVPVWK gp160(36-46) A*68:01, A11 human epitope
          VTVYYGVPVWK gp160(36-46) A*11:01 human, mouse epitope
          VTVYYGVPVWr gp160(36-46) susceptible form
          VTiYYGVPVWK gp160(36-46) susceptible form
          VTVYdGVPVWK gp160(36-46) non-susceptible form
          VTVYYGVPiWK gp160(36-46) susceptible form
          iTVYYGVPVWr gp160(36-46) susceptible form
          VTiYYGVPVWr gp160(36-46) susceptible form
          VTVYdGVPVWr gp160(36-46) non-susceptible form
          VTVYYGiPVWr gp160(36-46) susceptible form
          VTVYYGVPVrr gp160(36-46) non-susceptible form
          VTVYYGVPVWK gp160(36-46) A3 human epitope
          VTVYYGVPVWK gp160(36-46) A3 supertype human, mouse epitope
          VTVYYGVPVWK gp160(36-46) A*68:01 human epitope
          VTVYYGVPVWr gp160(36-46) observed variant
          VTVYYGVPVWKE gp160(36-47) A*03, A*11, A*68:01, C*07 human epitope
           TVYYGVPVW gp160(37-45) A*03, A*11 human epitope
           TVYYGVPVW gp160(37-45) B*35:01 human epitope
           TVYYGVPVW gp160(37-45) B*57:03, B*58:01 human epitope
           TVYYGIPVW gp160(37-45) human epitope
           TVYYGVPVW gp160(37-45) human epitope
           TVYYGVPVW gp160(37-45) human epitope
           TVYYGVPMW gp160(37-45) human epitope
           TVYYGVPVW gp160(37-45) human epitope
           TVYYGVPVWK gp160(37-46) A*02, A*11 human epitope
           TVYYGVPVWK gp160(37-46) A*03 human epitope
           TVYYGVPVWK gp160(37-46) A*03 human epitope
           TVYYGVPVWK gp160(37-46) A*03 human epitope
           TVYYGVPVWK gp160(37-46) A*03 human epitope
           TVYYGVPVWK gp160(37-46) A*03, A*11 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TiYYGVPVWK gp160(37-46) diminished response; escape documented in this paper; susceptible form
           TiYYGVPVWr gp160(37-46) diminished response; escape documented in this paper; susceptible form
           TVYYGVPagr gp160(37-46) diminished response; escape documented in this paper; susceptible form
           TVhYGVPVWr gp160(37-46) diminished response; escape documented in this paper; non-susceptible form
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01 human epitope
           TVYYGVPVWK gp160(37-46) A*03:01, A*68:01 human epitope
           TVYYGVPVWr gp160(37-46) observed variant
           TVYYGVPVWK gp160(37-46) A11 transgenic mouse epitope
           TVYYGVPVWK gp160(37-46) A11, A3 human epitope
           TVYYGVPVWK gp160(37-46) A11, A3 human epitope
           TVYYGVPVMK gp160(37-46) A11, A3, A68 epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWr gp160(37-46) susceptible form; subtype-specific susceptible form
           TVYYGVPVWt gp160(37-46) susceptible form; subtype-specific susceptible form
           aVYYGVPVWK gp160(37-46) susceptible form; subtype-specific susceptible form
           AVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A3 human epitope
           TVYYGVPVWK gp160(37-46) A*32 human epitope
           TVYYGVPVWK gp160(37-46) A*34 human epitope
           TVYYGVPVWK gp160(37-46) A*36 human epitope
           TVYYGVPVWK gp160(37-46) A3 supertype human epitope
           TVYYGVPVWK gp160(37-46) B*15:40 human epitope
           TVYYGVPVWK gp160(37-46) B*18 human epitope
           TVYYGVPVWK gp160(37-46) B*42:02 human epitope
           TVYYGVPVWK gp160(37-46) human epitope
           TVYYGVPVWKEAKTTLF gp160(37-53) A*32:01 human epitope
           TVYYGVPVWKEAKTTLF gp160(37-53) A*43:01 human epitope
           TVYYGVPVWKEAKTTLF gp160(37-53) B*58:01 human epitope
           TVYYGVPVWKEAKTTLF gp160(37-53) C*18 human epitope
           TVYYGVPVWKEATTTLF gp160(37-53) human epitope
           TVYYGVPVWKEAkTTLF gp160(37-53) subtype-specific susceptible form
           TVYYGVPVWKEATTTLF gp160(37-53) human epitope
            VYYGVPVWKEA gp160(38-48) Cw7 human epitope
            VYYGVPVWKEA gp160(38-48) Cw7 epitope
            VYYGVPVWrEA gp160(38-48) observed variant
            VYYGVPVWKEATTTL gp160(38-52) mouse epitope
            VYYGVPVWKEATTTL gp160(38-52) mouse epitope
             YYGVPVWKDAETTLF gp160(39-53) B*35:01, B*55:01 human epitope
             YYGVPVWKeAtTTLF gp160(39-53) susceptible form
               GVPVWKEATTT gp160(41-51) B*35 human epitope
                VPVWKEATT gp160(42-50) human epitope
                VPVWKEATTT gp160(42-51) A*68:02 human epitope
                VPVWKEATTT gp160(42-51) B*35:02, B*35:03, B*53:01 human epitope
                VPVWKEATTT gp160(42-51) B*39 human epitope
                VPVWKEATTT gp160(42-51) B55 human epitope
                VPVWKEATTT gp160(42-51) B55 human epitope
                VPVWKEATTT gp160(42-51) B55 human epitope
                VPVWKEATTT gp160(42-51) B*55:01, B55 human epitope
                VPVWKEAkTT gp160(42-51) observed variant
                VPVWrEAnTT gp160(42-51) observed variant
                VPVWKEATTT gp160(42-51) B*55:01 human epitope
                VPVWKEATTT gp160(42-51) B*81 human epitope
                VPVWKEATTT gp160(42-51) C*01 human epitope
                VPVWKEATTTL gp160(42-52) A*23 human epitope
                VPVWKEATTTL gp160(42-52) B*35 human epitope
                VPVWKEATTTL gp160(42-52) B*35 human epitope
                VPVWKEATTTL gp160(42-52) B35 human epitope
                VPVWKEATTTL gp160(42-52) B35 human epitope
                VPVWKEATTTL gp160(42-52) B35 human epitope
                VPVWKEATTTL gp160(42-52) B35 human epitope
                VPVWKEAdTTL gp160(42-52) subtype-specific susceptible form
                VPVWrdAdTTL gp160(42-52) subtype-specific susceptible form
                VPVWKdAeTTL gp160(42-52) subtype-specific susceptible form
                VPVWKEATTTL gp160(42-52) B35 human epitope
                VPVWKEATTTL gp160(42-52) B*35:01 human epitope
                VPVWKEATTTL gp160(42-52) B*35:01 human epitope
                VPVWKEATTTL gp160(42-52) B*35:01 human epitope
                VPVWKEATTTL gp160(42-52) B*35:01 human epitope
                VPVWKEAkTTL gp160(42-52) observed variant
                VPVWKKATTTL gp160(42-52) B*35:01 human epitope
                VPVWKEATTTL gp160(42-52) B*39 human epitope
                VPVWKEAKTTL gp160(42-52) B*53:01 human epitope
                VPVWKEAKTTL gp160(42-52) B*53:01 human epitope
                VPVWKEATTTL gp160(42-52) B*73 human epitope
                VPVWKEATTTL gp160(42-52) B*81 human epitope
                VPVWKEATTTL gp160(42-52) human epitope
                VPVWKEATTTL gp160(42-52) human epitope
                VPVWKEATTTLFCAS gp160(42-56) mouse epitope
                VPVWKEATTTLFCASDAK gp160(42-59) human epitope
                VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
                VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
                VPVWKEATTTLsrASDAKAY gp160(42-61) observed variant
                aPVWKEATTTLFCASDAKAY gp160(42-61) observed variant
                VPVWKEATTTLFrASDAKAY gp160(42-61) observed variant
                VPVWKEATTTLFCvSDAKAY gp160(42-61) observed variant
                VPVWKEATTTLFCAtDAKAY gp160(42-61) observed variant
                VPVWKEATTTLFyASDAKAY gp160(42-61) observed variant
                VPVWKEATTTpFCASDAKAY gp160(42-61) observed variant
                VPaWKEATTTLFCASDAKsY gp160(42-61) observed variant
                VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
                VPVWKEATTTLFCASDAKAY gp160(42-61) human epitope
                  VWKDAETTL gp160(44-52) B*38:01 human epitope
                  VWKDAETTL gp160(44-52) human epitope
                  VWKEATTTLF gp160(44-53) B55 human epitope
                  VWKDAKTTLF gp160(44-53) human epitope
                  VWKEATTTLF gp160(44-53) human epitope
                  VWKDAETTLF gp160(44-53) human epitope
                  VWKEATTTLF gp160(44-53) human epitope
                  VWKDAETTLF gp160(44-53) human epitope
                  VWKDAKTTLF gp160(44-53) human epitope
                  VWKEAKTTLF gp160(44-53) human epitope
                    KEATTTLFCASDAKA gp160(46-60) mouse epitope
Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health